Skip to main content

Human Genome Sciences And Transgene Sign Gene Therapy Drug Deal

Premium

ROCKVILLE, Md.--Human Genome Sciences here and French biotechnology company Transgene announced in early March a 10-year agreement to accelerate the development of novel gene therapy drugs. HGS will combine its genomics database with Transgene's broad technology platform of gene delivery systems, the companies said.

Transgene will have rights to exclusively license and sublicense up to 10 genes and to develop, manufacture, and commercialize any resulting gene therapy products worldwide.

HGS will take a 10 percent interest in Trangene's equity, and Transgene will pay an initial licensing fee and research funding in an amount equal to the proceeds to Trangene from the HGS purchase. Transgene will pay royalties on future sales and partnering revenues to HGS.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.